logo
logo
CLPT stock ticker logo

ClearPoint Neuro, Inc.

NASDAQ•CLPT
CEO: Mr. Joseph Michael Burnett
セクター: Healthcare
業種: Medical - Devices
上場日: 2012-05-22
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
連絡先情報
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, 92075, United States
888-287-9109
www.clearpointneuro.com
時価総額
$312.36M
PER (TTM)
-11.6
23.8
配当利回り
--
52週高値
$30.10
52週安値
$8.27
52週レンジ
10%
順位55Top 80.0%
2.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$10.41M+0.00%
直近4四半期の推移

EPS

-$0.27+0.00%
直近4四半期の推移

フリーCF

-$12.13M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Total Revenue Rises 18% Total revenue reached $37.0M USD, marking an 18% increase driven by product sales growth across segments.
Product Sales Surge 28% Product revenue grew 28% to $23.9M USD; neurosurgery disposable sales increased 44% year-over-year.
IRRAS Acquisition Closed Completed IRRAS acquisition in Q4 2025, expanding portfolio into neurocritical care with IRRAflow system integration.
Gross Margin Remains Stable Gross profit reached $22.7M USD; gross margin held steady at 61% despite increased operating costs.

リスク要因

Net Loss Widens Significantly Net loss increased 35% to $(25.5M) USD in 2025; sustained profitability remains uncertain given ongoing investments.
High Customer Revenue Concentration Significant customer concentration risk exists; top five hospital customers accounted for 21% of 2025 disposable revenues.
Operating Expenses Increase General and administrative expenses rose 38% to $16.5M USD, driven by IRRAS acquisition integration costs.
Market Adoption Uncertainty Future growth hinges on achieving broad market adoption for ClearPoint and IRRAflow systems against established competitors.

見通し

Anticipated Future Funding Needs Expect need for additional capital following IRRAS acquisition to fund commercialization and integration efforts through 2026.
Expand Installed Base Future objectives depend on expanding installed base and procedure volumes for both ClearPoint and IRRAflow platforms.
Biologics Partner Pipeline Over 60 partners evaluate products for gene/cell therapy delivery; success depends on partner clinical trial outcomes.
Cybersecurity Integration Planned Expect to fully integrate IRRAS cybersecurity governance structure and risk management framework throughout 2026.

同業比較

売上高 (TTM)

INNV stock ticker logoINNV
$912.10M
+13.1%
VREX stock ticker logoVREX
$854.40M
+4.1%
MYGN stock ticker logoMYGN
$824.50M
-1.6%

粗利益率 (最新四半期)

LAB stock ticker logoLAB
83.5%
-3.2pp
SIBN stock ticker logoSIBN
79.0%
+0.8pp
AKBA stock ticker logoAKBA
78.8%
+21.3pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
AXGN$1.94B-103.9-13.4%8.7%
TYRA$1.89B-17.4-41.2%2.1%
OLMA$1.44B-9.3-42.9%0.2%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
7.1%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月11日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし